BMO Capital Downgrades Eidos Therapeutics (EIDX) to Market Perform

BMO Capital downgraded Eidos Therapeutics (NASDAQ: EIDX) from Outperform to Market Perform (from $73.26).

For an analyst ratings summary and ratings history on Eidos Therapeutics click here. For more ratings news on Eidos Therapeutics click here.

Shares of Eidos Therapeutics closed at $73.51 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
• Monster Beverage (MNST) cut to sell at Truist as its 'no longer see it as a high growth story'
• Needham Downgrades HashiCorp Inc (HCP) to Hold